NCT00954278 2019-11-15
Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
University of Wisconsin, Madison
Phase 1 Completed
Clinical Trials
10 trialsNCT00543335 2018-11-15
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01005797 2017-03-03
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Phase 1 Completed
NCT00933777 2016-05-25
SORAVE
University of Cologne
Phase 1 Completed
NCT00533585 2016-02-10
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00466232 2015-12-16
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
HealthPartners Institute
Phase 1 Completed
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00870532 2013-11-04
Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer
National Cancer Centre, Singapore
Phase 1 Completed
NCT00635791 2013-06-20
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
University of Colorado, Denver
Phase 1 Completed